Stockreport

Zenas BioPharma Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Zenas BioPharma, Inc.  (ZBIO) 
PDF - Obexelimab marketing applications for the treatment of IgG4-RD expected to be submitted to the FDA in Q2 2026 and the EMA in H2 2026 based on the Phase 3 INDIGO trial [Read more]